# EDGAR Filing Document

**Accession Number:** 0002082327
**File Stem:** 0000000000-25-009420
**Filing Date:** 2025-9
**Character Count:** 2521
**Document Hash:** 6dc9dde1e7ce9af388f885718f08a8e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009420.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0000000000-25-009420

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250902

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 216 Pharmacy Corp
- **CENTRAL INDEX KEY:** 0002082327
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 334781829
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 024-12651

**BUSINESS ADDRESS:**
- **STREET 1:** 4400 N. SCOTTSDALE RD. #984
- **CITY:** SCOTTSDALE
- **STATE:** AZ
- **ZIP:** 85251
- **BUSINESS PHONE:** (480) 995-3797

**MAIL ADDRESS:**
- **STREET 1:** 4400 N. SCOTTSDALE RD. #984
- **CITY:** SCOTTSDALE
- **STATE:** AZ
- **ZIP:** 85251
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001096906-25-001425

## Text-Extract

```

                                                            September 2, 2025

Danny Williamson
CEO, President and Director
216 Pharmacy Corp
4400 N. Scottsdale Rd. Ste 984
Scottsdale, AZ 85251

       Re: 216 Pharmacy Corp
           Offering Statement on Form 1-A
           Filed August 25, 2025
           File No. 024-12651
Dear Danny Williamson:

       This is to advise you that we do not intend to review your offering
statement.

         We will consider qualifying your offering statement at your request.
In connection
with your request, please confirm in writing that at least one state has
advised you that it is
prepared to qualify or register your offering. If a participant in your
offering is required to
clear its compensation arrangements with FINRA, please have FINRA advise us
that it has no
objections to the compensation arrangements prior to qualification.

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Please contact Rebekah Reed at 202-551-5332 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Trade &
Services
cc:   Matt Stout

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._